Skip to main content
. 2021 Nov 24;11:585006. doi: 10.3389/fonc.2021.585006

Table 3.

The Univariable and multivariate analysis for the Bloodloss in operation.

Characteristic Univariable analysis Multivariable analysis
OR (95% CI) P value OR (95% CI) P value
Age <60 vs. ≥60 0.773 (0.350-1.704) 0.523
Gender (male/female) Male vs. Female 0.247 (0.101-0.602) 0.002 0.343 (0.116-1.016) 0.054
BMI <24 vs. ≧24 2.94 (1.253-7.160) 0.014 3.264 (1.174-9.076) 0.023
Differentiate Well & Moderate vs. Poor 1.459 (0.625-3.407) 0.382
Lauren classification Intestinal 0.596
Diffuse 0.696 (0.247-1.962) 0.494
Mix 0.636 (0.255-1.587) 0.332
Borrmann Type I-II vs. III-IV 0.818 (0.318-2.096) 0.676
Tumor size <4 cm vs. ≥4cm 2.374 (1.052-5.357) 0.037 1.886 (0.702-5.062) 0.208
Tumor location Cardia 0.655
Body 0.659 (0.254-1.708) 0.390
Antrum 0.520 (0.178-1.518) 0.232
Whole 0.867 (0.178-4.210) 0.859
Fib 0-1 vs 2-3 0.929 (0.197-4.383) 0.925
Edema 0-1 vs 2-3 NA 0.999
Effusion 0-1 vs 2-3 NA 0.999
Total score of GTRs 0-3 vs 4-9 1.286 (0.57-2.900) 0.545
RECIST CR & PR vs. PD & SD 0.909 (0.413-2.001) 0.813
Operation time <300 min vs. ≥300 min 1.376 (0.620-3.054) 0.433
Operation type Lap vs. Open 4.400 (1.415-13.678) 0.010 3.373 (0.919-12.379) 0.067
Resection type Partial vs. Total 3.431 (1.500-7.848) 0.003 2.458 (0.893-6.765) 0.082
T stage cT2 0.736
cT3 0.588 (0.096-3.617) 0.567
cT4 0.783 (0.132-4.623) 0.787
N stage cN (-) vs. cN (+) 5.800 (1.140-29.499) 0.034 12.06 (1.896-76.693) 0.008
M stage cM0 vs. cM1 2.642 (0.521-13.404) 0.241
TNM stage 2 0.362
3 1.164 (0.514-2.635) 0.716
4 4.957 (0.548-44.844) 0.154
Chemo regimen XELOX vs. Other 2.294 (0.582-9.042) 0.235
Chemo cycle 3 cycles vs. Other 0.823 (0.307-2.205) 0.699
Chemo complications Positive vs. negative 1.255 (0.343-4.591) 0.732

OR, Odds ratio; CI, confidence interval;BMI Body, mass index; RECIST, Response Evaluation Criteria in Solid Tumors; Lap, laparoscopy surgery; Open, open surgery; TRG, tissue regression grade; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NA, not available.